1. Home
  2. ZS vs BIIB Comparison

ZS vs BIIB Comparison

Compare ZS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zscaler Inc.

ZS

Zscaler Inc.

HOLD

Current Price

$236.40

Market Cap

52.0B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$174.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZS
BIIB
Founded
2007
1978
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.0B
24.2B
IPO Year
2018
1991

Fundamental Metrics

Financial Performance
Metric
ZS
BIIB
Price
$236.40
$174.61
Analyst Decision
Buy
Buy
Analyst Count
34
22
Target Price
$323.73
$177.40
AVG Volume (30 Days)
2.4M
2.0M
Earning Date
11-25-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
10.97
Revenue
$2,833,272,000.00
$10,065,900,000.00
Revenue This Year
$26.93
$3.61
Revenue Next Year
$19.33
N/A
P/E Ratio
N/A
$15.86
Revenue Growth
23.24
4.77
52 Week Low
$164.78
$110.04
52 Week High
$336.99
$185.17

Technical Indicators

Market Signals
Indicator
ZS
BIIB
Relative Strength Index (RSI) 26.17 55.41
Support Level $237.77 $169.24
Resistance Level $245.12 $180.79
Average True Range (ATR) 7.41 5.36
MACD -0.93 -1.56
Stochastic Oscillator 4.27 33.70

Price Performance

Historical Comparison
ZS
BIIB

About ZS Zscaler Inc.

Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: